Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.
FAIL · Does not pass the screen
3.29 USD
At the last full screen 2026-09-16
Screened 2026-09-16 · the tape above runs as of 11:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Cronos Group Inc. holds its Accumulation at $3.29. Consolidating, no directional conviction, held for 25 days.
As held on the ledger · 2026-09-16
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 25 days
Price at the screen
$3.29
Valuation
17.32 trailing · -82.25 forward price to earnings
Values screen
FAIL· score 64.7
Beta
1.28
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.13%
Below 33%
Interest-bearing debt is just 0.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
3.34%
Below 33%
Cash held in interest-bearing accounts and securities is 3.3% of assets, under the one-third limit.
Pass
Receivables
68.99%
Below 49%
Money owed to the company is 69.0% of assets, above the 49% limit.
Fail
Revenue purity
27.26%
Below 5%
27.3% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-16 screen. The gold marker is the market price at the same screen. The price runs 23.8% above the base estimate.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cannabis Sales Rise Yet Losses Keep Mounting
Picture a grower shipping dried flowers, oils and edibles from Canada into new markets. Cronos is lifting revenue 40% a year, yet it still runs at a 1% negative profit margin and zero return on equity while the shares sit 9% above our fair value.
The forward multiple is deeply negative and only one analyst even follows the name. Without a clear moat or path to sustained profits, the business offers no margin of safety and earns an opportunity rating of none despite clearing the ethical screen.
Currency swings, shifting cannabis rules and thin cash generation keep risk elevated. The valuation already prices in better days that have not arrived. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Canada and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRON trades on Nasdaq (the company is based in Canada). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-25Markup$3.16+13.3%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-07-25Markup$2.79+1.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-07-18Markup$2.74+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (1 analysts) rates it none, with a mean price target of $2.
2026-07-03Markup$2.74+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$2.74Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
